X4 Pharmaceuticals Inc (NASDAQ:XFOR) has a beta value of 0.37 and has seen 2.0 million shares traded in the last trading session. The company, currently valued at $138.58M, closed the last trade at $0.83 per share which meant it gained $0.03 on the day or 3.54% during that session. The XFOR stock price is -126.51% off its 52-week high price of $1.88 and 36.14% above the 52-week low of $0.53. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.95 million shares traded. The 3-month trading volume is 3.02 million shares.
The consensus among analysts is that X4 Pharmaceuticals Inc (XFOR) is Buy stock at the moment, with a recommendation rating of 1.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.01.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
X4 Pharmaceuticals Inc (NASDAQ:XFOR) trade information
Sporting 3.54% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the XFOR stock price touched $0.83 or saw a rise of 2.35%. Year-to-date, X4 Pharmaceuticals Inc shares have moved -1.59%, while the 5-day performance has seen it change 8.68%. Over the past 30 days, the shares of X4 Pharmaceuticals Inc (NASDAQ:XFOR) have changed -18.30%. Short interest in the company has seen 13.88 million shares shorted with days to cover at 5.49.
Wall Street analysts have a consensus price target for the stock at $3, which means that the shares’ value could jump 72.33% from current levels. The projected low price target is $3 while the price target rests at a high of $5. In that case, then, we find that the current price level is -502.41% off the targeted high while a plunge would see the stock gain -261.45% from current levels.
X4 Pharmaceuticals Inc (XFOR) estimates and forecasts
Figures show that X4 Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 6.81% over the past 6 months, with this year growth rate of 3.51%, compared to 15.20% for the industry.
6 analysts offering their estimates for the company have set an average revenue estimate of 280k for the current quarter. 7 have an estimated revenue figure of 1.72M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 73.95% over the past 5 years.
XFOR Dividends
X4 Pharmaceuticals Inc is expected to release its next earnings report in August this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
X4 Pharmaceuticals Inc (NASDAQ:XFOR)’s Major holders
Investors are also buoyed by the number of investors in a company, with X4 Pharmaceuticals Inc top two institutional holders are BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with over 16.92 million shares worth more than $23.51 million. As of 2024-03-31, BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC held 9.5133% of shares outstanding.
The other major institutional holder is NEA MANAGEMENT COMPANY, LLC, with the holding of over 14.99 million shares as of 2024-03-31. The firm’s total holdings are worth over $20.83 million and represent 8.4284% of shares outstanding.
